Corey R Roos1, Krysten W Bold1, Katie Witkiewitz2, Robert F Leeman1,3, Kelly S DeMartini1, Lisa M Fucito1, William R Corbin4, Karl Mann5, Henry R Kranzler6, Stephanie S O'Malley1. 1. Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA. 2. Department of Psychology, University of New Mexico, Albuquerque, NM, USA. 3. Department of Health Education and Behavior, University of Florida, Gainesville, FL, USA. 4. Department of Psychology, Arizona State University, Tempe, AZ, USA. 5. Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. 6. Perelman School of Medicine, University of Pennsylvania and Crescenz VAMC, Philadelphia, PA, USA.
Abstract
AIMS: Theory-driven, exploratory study to: (i) identify a reward drinking phenotype in young adults; (ii) evaluate this phenotype as a predictor of naltrexone response; and (iii) examine mechanisms of naltrexone in reward drinkers. DESIGN: Secondary analysis of a randomized controlled trial. SETTING: USA. PARTICIPANTS: A total of 128 young adult (ages 18-25) heavy drinkers. INTERVENTIONS: Naltrexone versus placebo. MEASUREMENTS: Daily surveys assessed affect, urge, drinking, and context. The Drinking Motives Questionnaire was used to identify phenotypes based on reward (enhancement motives) and relief (coping motives) drinking. FINDINGS: We identified three profiles: "Low reward/Low relief" (14.1%; low enhancement/low coping motives); "Reward drinkers" (62.2%; high enhancement/low coping motives); and "High reward/High relief" (22.7%; high enhancement/high coping motives). Among reward drinkers (versus low profile), naltrexone significantly reduced percent days drinking to intoxication (blood alcohol concentration [BAC] ≥0.08) (PDI) (d = 0.56; 95% CI [0.17, 0.96]) and percent high intensity drinking days (PHID) (8/10 drinks for women/men) (d = 0.32; 95% CI [0.01, 0.68]). Among the high reward/high relief profile drinkers (versus low profile), naltrexone reduced PHID (d = 0.69; 95% CI [0.02, 1.50]). Using profile-informed cutoffs and observed scores (for clinical applicability): (i) among cutoff-derived reward drinkers, we found a medium-to-large (d = 0.66; 95% CI [0.24, 1.16]) and small effect (d = 0.28; 95% CI [0.04, 0.72]) of naltrexone in reducing PDI and PHID, respectively; and (ii) among the cutoff-derived high reward/high relief subgroup, we found a medium-to-large effect (d = 0.63; 95% CI [0.05, 1.1]) of naltrexone in reducing PHID. Among reward drinkers (not other profiles), naltrexone reduced drinking on days a drinking event occurred by weakening the within-day association between positive affect and urges (P < 0.05). CONCLUSIONS: Naltrexone has pronounced effects in reducing risky drinking among young adult reward drinkers (high reward/low relief) by reducing urges on days when individuals have higher positive affect and are exposed to a drinking event. Naltrexone also appears to reduce risky drinking among young adult high reward/high relief drinkers, but not via the same mechanism.
AIMS: Theory-driven, exploratory study to: (i) identify a reward drinking phenotype in young adults; (ii) evaluate this phenotype as a predictor of naltrexone response; and (iii) examine mechanisms of naltrexone in reward drinkers. DESIGN: Secondary analysis of a randomized controlled trial. SETTING: USA. PARTICIPANTS: A total of 128 young adult (ages 18-25) heavy drinkers. INTERVENTIONS: Naltrexone versus placebo. MEASUREMENTS: Daily surveys assessed affect, urge, drinking, and context. The Drinking Motives Questionnaire was used to identify phenotypes based on reward (enhancement motives) and relief (coping motives) drinking. FINDINGS: We identified three profiles: "Low reward/Low relief" (14.1%; low enhancement/low coping motives); "Reward drinkers" (62.2%; high enhancement/low coping motives); and "High reward/High relief" (22.7%; high enhancement/high coping motives). Among reward drinkers (versus low profile), naltrexone significantly reduced percent days drinking to intoxication (blood alcohol concentration [BAC] ≥0.08) (PDI) (d = 0.56; 95% CI [0.17, 0.96]) and percent high intensity drinking days (PHID) (8/10 drinks for women/men) (d = 0.32; 95% CI [0.01, 0.68]). Among the high reward/high relief profile drinkers (versus low profile), naltrexone reduced PHID (d = 0.69; 95% CI [0.02, 1.50]). Using profile-informed cutoffs and observed scores (for clinical applicability): (i) among cutoff-derived reward drinkers, we found a medium-to-large (d = 0.66; 95% CI [0.24, 1.16]) and small effect (d = 0.28; 95% CI [0.04, 0.72]) of naltrexone in reducing PDI and PHID, respectively; and (ii) among the cutoff-derived high reward/high relief subgroup, we found a medium-to-large effect (d = 0.63; 95% CI [0.05, 1.1]) of naltrexone in reducing PHID. Among reward drinkers (not other profiles), naltrexone reduced drinking on days a drinking event occurred by weakening the within-day association between positive affect and urges (P < 0.05). CONCLUSIONS: Naltrexone has pronounced effects in reducing risky drinking among young adult reward drinkers (high reward/low relief) by reducing urges on days when individuals have higher positive affect and are exposed to a drinking event. Naltrexone also appears to reduce risky drinking among young adult high reward/high relief drinkers, but not via the same mechanism.
Authors: Ashley N Linden-Carmichael; Sara A Vasilenko; Stephanie T Lanza; Jennifer L Maggs Journal: Alcohol Clin Exp Res Date: 2017-09-05 Impact factor: 3.455
Authors: Megan E Patrick; Yvonne M Terry-McElrath; Deborah D Kloska; John E Schulenberg Journal: Alcohol Clin Exp Res Date: 2016-08-04 Impact factor: 3.455
Authors: Rainer Spanagel; Daniel Durstewitz; Anita Hansson; Andreas Heinz; Falk Kiefer; Georg Köhr; Franziska Matthäus; Markus M Nöthen; Hamid R Noori; Klaus Obermayer; Marcella Rietschel; Patrick Schloss; Henrike Scholz; Gunter Schumann; Michael Smolka; Wolfgang Sommer; Valentina Vengeliene; Henrik Walter; Wolfgang Wurst; Uli S Zimmermann; Sven Stringer; Yannick Smits; Eske M Derks Journal: Addict Biol Date: 2013-11 Impact factor: 4.280
Authors: Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney Journal: Addiction Date: 2012-10-17 Impact factor: 6.526
Authors: Daniel E Jonas; Halle R Amick; Cynthia Feltner; Georgiy Bobashev; Kathleen Thomas; Roberta Wines; Mimi M Kim; Ellen Shanahan; C Elizabeth Gass; Cassandra J Rowe; James C Garbutt Journal: JAMA Date: 2014-05-14 Impact factor: 56.272
Authors: Victoria R Votaw; Karl Mann; Henry R Kranzler; Corey R Roos; Helmut Nakovics; Katie Witkiewitz Journal: Drug Alcohol Depend Date: 2021-12-31 Impact factor: 4.492